REVIEW ON ANDROGENIC INDUCED ALOPECIA

Aniket Pachpor[1], Akshy Jagtap[2], Samiksha Khobragade[3], Padmaja Hajare[4], Pornima Mahalkar [5]

Vidyniketan College of Pharmacy, Anjangaon Surji, Dist - Amravati, Maharashtra, India

ABTRACT

Androgenetic alopecia (AGA), a current condition affecting millions worldwide, profoundly impacts tone-regard, confidence, and quality of life. This review delves into the complications of AGA, exploring its multifactorial etiology, polygenetic base, and the intricate interplay between androgens, genetics, and terrain. We examine current remedial options, their efficacity, and implicit adverse goods, pressing the need for individualized treatment approaches. As exploration advances, we regard promising new perspectives on AGA operation, emphasizing the significance of empathy, patient education, and holistic care in mollifying the emotional risk of this condition.

KEYWORDS: Androgenetic alopecia, hair loss, androgens, genetics, treatment, quality of life, patient-center care.

1. INTRODUCTION

The hallmark of androgenetic alopecia (AGA), also known as male and female pattern hair loss, is the non-scarring progressive shrinkage of the hair follicle with a pattern distribution in susceptible men and women [1]. It is one of the most common causes for a hair consultation [2]. According to epidemiologic data, the prevalence of AGA rises with age, affecting 80% of Caucasian men and 40% to 50% of Caucasian women during their lifetimes [3]. AGA was found in 14.1% of Korean men of all ages, indicating a lower prevalence in the Asian population [4]. According to a study, the frequency of AGA in the African population was 3.5% in women and 14.6% in males [5]. The etiology of AGA is complicated and polygenetic [6]. Male AGA [7]. AGA affects patients' self-esteem and quality of life, and patients' expectations for therapy outcomes are usually higher than the actual outcomes. It is important to clarify that the main goal of treatment is to prevent further thinning and to stop its progression, and that regrowth and improvement may not always be achieved. (MAGA) is clearly an androgen-dependent disorder, and although the mode of inheritance is unknown, a hereditary propensity is observed. Despite the high prevalence of AGA, there aren't many authorized treatment alternatives. This article's goal is to examine the available treatment choices, any potential side effects, and emerging approaches to treating AGA [8].

Androgenetic alopecia (AGA), also known as androgenic Alopecia or male pattern baldness, is the most prevalent kind of progressive hair loss. The severity, age of start, and scalp location of hair loss differ among AGA, a polygenetic disorder [9].

The characteristic "horseshoe" pattern of hair loss in men generally affects the temporal and vertex region while occipital region is left complete. Age and race have an impact on the frequence and prevalence of AGA. We know that over to 30 of white males will have AGA by the age of 30, 50 by the age of 50, and 80 by the age of 70, grounded on the spare frequence data that's presently available (10). Compared to Caucasians, Chinese, Japanese, and African Americans are less affected (11). AGA causes the hair follicle to gradationally shrink, which results in the terminal hair's vellus transformation. This is due to a change in the dynamics of the hair cycle the duration of the telogen phase increases while the anagen phase gradationally decreases (12). The new anagen hair grows shorter as the duration of the anagen phase dictates hair length, eventually performing in a bald appearance (13).

Hamilton mentioned the interaction of androgens, genetics, and age in the genesis of AGA in 1951 [14]. Hamilton's research on hypogonadal males demonstrated that androgens were necessary for the development of common baldness: castrated individuals did not develop AGA, and testosterone injections might cause AGA in castrated men. Even though androgens are responsible for these alterations, most of the molecular mechanisms underlying them are unknown, which limits the variety of available treatments. AGA predisposition is largely influenced by genetics. Twin studies show that strong concordance rates for monozygotic twins range from 80 to 90%. Family analyses show that men who have bald fathers are much more likely to develop AGA [15], while men who do not have balding fathers are much less likely to do so. However, a positive family history on the mother's or maternal grandfather's side also raises the risk of having AGA [16]. This transmission across numerous generations indicates that a single main gene may be involved.

Osborn suggested in 1916 that the AGA pattern would be compatible with an autosomal dominant characteristic [17]. After reviewing the genetics of AGA, Kuster and Happle came to the conclusion that Osborn's hypothesis was of uncertain value because it had not been adequately investigated [18]. They came to the conclusion that a polygenic mode of inheritance was more plausible after analyzing five earlier investigations. The idea that AGA is a polygenic trait is supported by current scientific research, however its pathophysiology and genetics are still unclear. Variant regions of the androgen receptor gene, which is found on the X chromosome, have been linked to significant correlations. Most likely, a number of genetic and environmental variables interact to cause AGA, making it a complex condition [19].

2. HISTORY AND PHYSICAL

Following adolescence, androgenetic alopecia presents as a pattern of gradual and consistent hair loss. Bitemporal thinning of the frontal scalp usually precedes involvement of the vertex in men (see image). Androgenetic alopecia with a male pattern. Women's hair thinning is more scattered and frequently centered on the scalp's crown, leaving the frontal hairline intact [20].

Assessing the pattern and degree of hair loss is part of the physical evaluation of an individual with androgenetic alopecia. Male-pattern baldness is often categorized using the Norwood-Hamilton scale, whereas female-pattern baldness is classified using the Ludwig scale. These scales aid in classifying the degree of hair loss and directing the choice of treatment [21]. A medical professional may also check for shrunken hair follicles, increased hair shedding, and general scalp health during a physical examination. A

noninvasive method called dermoscopy, which uses a special magnifying device, can help identify androgenetic alopecia by making it easier to see the hair follicles. It's crucial to remember that although androgenetic alopecia is the most frequent cause of hair loss, other elements like illnesses, drugs, and stress can also cause hair loss and thinning. For case, telogen scrap, which happens 1 to 6 months after a stressor causes a lesser chance of the hair to transition from the anagen phase to the telogen phase, performing in an adding number of hair follicles in the exogen phase, constantly reveals pattern baldness in women [22]. Another illustration is early androgenetic alopecia, which is considered the manly counterpart of polycystic ovarian pattern and is classified as being before the age of thirty [23].

1. ANDROGEN

A class of steroid hormones known as androgens is essential for the development and conservation of mannish traits, reproductive processes, and general, health [24].

Types of Androgens

1. **Testosterone** The primary manly coitus hormone, testosterone, is necessary for muscular growth, desire, spermatogenesis [25].
2. **Dihydrotestosterone** (DHT) A strong testosterone metabolite that contributes to prostate development and manly pattern baldness [26].

3.Androstenedione: The gonads and adrenal glands create this precursor to estrogen and testosterone [27].

Functions of Androgens

Masculinization: - The development of masculine secondary sex traits such facial hair, a deep voice, and muscle bulk is known as masculinization [28].

Spermatogenesis: - Control of fertility and sperm production [29].

Libido: - Impact on erectile function and sex drive [30].

Bone density: - Androgens help to preserve bone density and health [31].

Regulation of Androgen

Hypothalamic-pituitary-gonadal axis: - Complex feedback loop regulating androgen production [32].

Luteinizing Hormone (LH): - Stimulates testosterone production in the testes [33].

Importance of Androgens

1.**Male reproductive health:** The production of sperm, fertility, and male reproductive function all depend on androgens [34].

2. Secondary sex traits: Androgens affect libido and determine masculine physical attributes [35].

3. General health: Androgens affect muscular mass, bone density, and general health [36].

Androgen-Related Disorders

1. **Hypogonadism:** Symptoms such as weariness and poor libido are caused by low testosterone levels [37].
2. **2. Androgen excess:** Hyperandrogenism is a defining feature of conditions such as polycystic ovarian syndrome (PCOS) in women [38].
3. **Prostate problems:** Prostate growth and cancer are influenced by androgens [39].

Therapeutic Applications

1.Testosterone replacement therapy (TRT): - Hypogonadism treatment [40].

2.Androgen deprivation therapy (ADT): - Prostate cancer is treated with androgen deprivation therapy (ADT) [41].

3. ANDROGEN RECEPTOR ANTAGONISTS

Androgen receptor antagonists are not approved by the FDA but are frequently used off-label for the treatment of FAGA. Literature on the therapeutic effect of the androgen ln Receptor antagonists—spironolactone, cyproterone acetate, and flutamide is scarce, particularly in patients without Hyperandrogenism, and none of the studies is of high-quality evidence. Most studies have evaluated the efficacy of these drugs, singly or in association, in women with Hyperandrogenism, mainly with acne and hirsutism. It is Important to highlight that these agents are an off-label Prescription for the treatment of all of these conditions and They require safe contraception due to their teratogenicity [42].

1.Spironolactone

Because it lowers testosterone levels and blocks androgen receptors in target tissues, the potassium-sparing diuretic Spironolactone is regarded as an antiandrogen [43]. It has a good long-term safety profile and has been used for more than 20 years to treat FAGA at doses of 50–200 mg per day [44]. conducted an open-label study to assess the effects of cyproterone acetate and spironolactone in 80 women with FAGA for at least 12 months. Forty of the women received 200 mg of cyproterone acetate daily, and 40 received 50 mg of cyproterone acetate daily, or 100 mg for 10 days per month if premenopausal. There was no discernible difference between the two groups.

According to the findings, oral antiandrogens bettered hair regrowth in 44 of cases, had no effect on 44, and caused hair loss to persist in 10 of cases [45]. Spironolactone has the implicit to have cure dependent negative goods in terms of safety. Because of its antiandrogenic (bone soreness, irregular period) and diuretic (hyperkalemia, hypotension, fatigue, weight loss, and increased frequence of urination goods). In a recent retrospective study, the rates of hyperkalemia were examined in 1165 healthy youthful women and 974

youthful women using spironolactone for acne. To determine the birth rate of hyperkalemia in this population, spironolactone was taken and not taken. The authors came to the conclusion that youthful, healthy women using spironolactone for acne had a similar rate of hyperkalemia. Given the birth rate of hyperkalemia in this population, it's suggested that healthy youthful women on spironolactone for acne don't bear frequent potassium monitoring (46). This knowledge may also be used to treat AGA in youthful, healthy women, which would relieve worries about covering hyperkalemia while taking spironolactone.

2. Cyproterone Acetate

Cyproterone acetate is an androgen receptor antagonist that lowers testosterone situations by reducing the product of luteinizing and follicle- stimulating hormones and directly prevents DHT from attaching to its receptors [47]. Although cyproterone acetate is accessible in the United States, it's available in the maturity of countries as an oral contraceptive lozenge (OCP) in combination with ethinyl estradiol and as a standalone drug. There are clashing results from the many studies that have been done on its remedial effectiveness in treating FAGA.

Peereboom-Wynia et al. [48] compared two groups of women over a year. One group had an OCP containing 50 grams of ethinyl estradiol and 2 mg of cyproterone acetate and 20 mg of cyproterone acetate on days 5–20 of the cycle and the other group had no treatment. The authors described a significant improvement on the anagen proportion in the treated group [49]. To compare cyproterone acetate 50 mg with an OCP ethinyl (estradiol 35 µg and cyproterone acetate 2 mg) and 2% topical minoxidil in combination with another OCP (ethinyl estradiol 30 lg and gestodene 75µg), Vexiau et al [50]. conducted a 12month RCT in 66 women. Overall, the findings indicated that the minoxidil 2% solution group had better results. Additionally, their study shown that cyproterone acetate was more effective in increasing the number of hairs in patients with signs of hyperandrogenism, whereas minoxidil 2% was more effective in increasing the number of hairs in patients without hyperandrogenism [51]. There were no differences between the two groups in the forenamed trial that compared cyproterone acetate and spironolactone in FAGA treatment [52]. Also, although there's no substantiation to support this claim, a subgroup study of a meta-analysis set up those cases with clinical pointers of hyperandrogenism respond better to remedy with cyproterone acetate for a time than do women without hyperandrogenism [53]. Hepatotoxicity, weight gain, dropped libido, bone soreness, and feminization of the manly fetus are some of the adverse goods of this drug.

3.Flutamide

An antiandrogen called flutamide effectively prevents androgens from binding to their receptor. Its use in FAGA has not yet been supported by any randomized placebo-controlled research [54].

A prospective analysis of 101 FAG patients, When flutamide (250, 125, or 62.5 mg/day) was compared to flutamide plus an OCP, alopecia scores showed a little improvement that persisted for up to two years. Due to hepatic impairment, a few of patients (4%) left the trial [55]. Furthermore, a randomized study found that after a year, flutamide 250 mg daily only produced a modest improvement in hyperandrogenic women, as reported using non-objective methods. Finasteride and cyproterone acetate did not work in this study [56]. However, Yazdabadi and Sinclair [57] described a patient who experienced hair growth with flutamide but did not

respond to topical minoxidil or oral spironolactone. According to one article [83], flutamide use is limited by the dose-dependent risk of severe hepatotoxicity (3/10,000 users), even though low dosages like 62.5mg/day may be effective and well-tolerated. Progestogens containing FAGA are among the other oral antiandrogens [58]. Furthermore, the previously cited meta-analysis found insufficient evidence to support the use of oral antiandrogens as a treatment for FAGA and a means of halting its growth [59]. Similarly, research on finasteride, cyproterone acetate, and spirolactone were excluded from a Cochrane comprehensive review. Only minoxidil has high-quality evidence as a therapy for FAGA, according to their analysis, which was not randomized or controlled [60].

4. ANTIANDROGEN THERAPIES

1.Finasteride: -

The only treatments for MAGA that have been approved by the US Food and Drug Administration (FDA) are finasteride 1 mg and minoxidil 2–5% solution (Table 1). The shrinkage of the hair follicle observed in MAGA is caused by finasteride, a Type 2 5a-reductase inhibitor that reduces the conversion of testosterone to dihydrotestosterone (DHT). The effectiveness of finasteride has been proven in numerous researches. With moderate quality of evidence, a systematic assessment of long-term usage of finasteride 1 mg daily by Mella et al. [61] found that 30% of patients had notable improvement. In a recent meta-analysis, Gupta and Charrette [62]. discovered Analogous results, demonstrating that 5a- reductase impediments are noticeably more effective than a placebo at adding the number of hairs. In individualities between the periods of 41 and 60, finasteride 1mg has also been demonstrated to be effective in treating MAGA; advancements have been noted by investigator assessments and worldwide photos. nevertheless, the Vertex/ medial crown regions and youngish individualities generally have advanced responses [63].

Finasteride drug should last a continuance because stopping it causes gradational hair loss that returns toper-treated situations within a year. From a safety perspective, finasteride has no important medication interactions and is neither hepatotoxic nor nephrotoxic. However, because this medication is processed in the liver, it is advised that patients with liver illness avoid using it [64]. In order to avoid a pregnant woman receiving finasteride during a blood transfusion, persons on this medicine should not donate blood due to its teratogenicity [65]. Finasteride's negative sexual effects are well-known and well-documented. These include erectile dysfunction, decreased libido, and decreased ejaculatory volume. Compared to 1 in the placebo group, about 2 of cases endured one or further sexual side goods when using finasteride [66]. Likewise, this threat was 3.8 in randomized controlled trials (RCTs) (compared to 2.1 for placebo). Treatment termination wasn't always necessary for sexual side goods [67]. Kaufman and associates [68]. It was shown that 1.8 of men between the periods of 18 and 41 educated reversible sexually affiliated side goods, compared to 1.1 in the placebo group. Compared to 5.1 of aged males aged 41 – 60, 8.7 of those using finasteride endured sexually affiliated side goods [69]. Furthermore, a recent meta-analysis showed no discernible difference in the outcome of "global sexual disturbance" between active therapies and a placebo [70]. There are safety concerns for both patients and dermatologists after a few uncontrolled trials have revealed depression and permanent sexual side effects in people treated with finasteride 1 mg for AGA [71].

Although there have been reports of endless sexual dysfunction in small uncontrolled studies, case reports, and post-marketing monitoring, its factual frequency seems to be truly low (lower than 1 inpost marketing data) [72]. Still, a new meta- analysis highlights that all clinical trials were patronized and none had respectable safety reporting, despite data from controlled trials showing a low frequency of sexual side goods and their forgiveness following treatment retirement [73]. stated Cases using 1mg of finasteride reported an improvement in their quality of life. Some MAGA cases substantiation extreme anxiety, which the medicine may not always help with. Gynecomastia is a fairly uncommon condition that can be unilateral or bilateral and can sometimes be painful [74].

A small number of case reports and randomized controlled studies have mooted spermatogenesis and fertility.

After long- term finasteride treatment, some authors observed a considerable change in semen characteristics and quality, which was reversed after stopping the medicine [75]. Finasteride 1mg daily for 48 weeks did n't significantly alter the semen parameters of 181 healthy actors, according to a double-eyeless, placebo-controlled trial (76). When 99 males were treated for benign prostatic hyperplasia (BPH) with either finasteride 5 mg or dutasteride 0.5mg, a randomized, double-eyeless, placebo- controlled study set up that only spermatozoid motility was significantly impacted [77]. It should be noted, still, that only men without a history of gestation were included in these trials. Finasteride should be stopped or indeed not recommended in cases with changes in semen analysis or fertility issues, according to data from fertility conventions (78). Men who take finasteride don't jeopardize a pregnant woman or her fetus since the amounts of finasteride in semen are extremely low [79]. Serum situations of prostate-specific antigen (PSA) are lower. Reduced prostatic DHT situations, a miracle that may conceal and defer an early opinion of prostate cancer, by roughly 50 while taking finasteride 1mg daily. Because of this, it's advised that men over 50 have their PSA base situations measured before beginning treatment [80]. In 2011, the FDA added to the safety labeling that, despite the fact that people using finasteride have a 25 lower chance of developing prostate cancer, there's an elevated threat of high- grade prostate cancer, grounded on two large randomized, placebo- controlled studies [81]. Finasteride does not, still, raise the prevalence of high- grade prostatic cancer, according to a recent meta- analysis [82]. Finasteride's advantages in treating MAGA necessitate long- term remedy, and cases should be completely informed of any implicit short- and long- term side goods.

Dermatologists should explicitly inquire about mood disorders and sexual side effects from their patients. Finasteride is used off-label for FAGA, and its effectiveness in treating women is not well proven. In case reports, case series, and uncontrolled trials, finasteride 2.5–5 mg has been shown to have positive effects in premenopausal and postmenopausal women [83]. Nevertheless, two sizable RCTs in postmenopausal women have demonstrated that finasteride 1 mg daily is ineffective [84]. Additionally, a Cochrane systematic review found no evidence that finasteride is more beneficial than a placebo [85]. In contrast, an Asian group conducted a non-controlled, non-randomized study in 2011 to evaluate the clinical response of finasteride 5 mg/day in 87 premenopausal and postmenopausal norm androgenic women over a 12-month period. The study found that 81% of the patients showed improvement as measured by global photographs, with a low incidence (4.7%) of mild and temporary adverse effects. The known teratogenicity of finasteride is another factor that

limits its usage in women, in addition to the lack of strong evidence. Finasteride might cause feminization of the male fetus; hence women of reproductive age should take it under stringent birth control measures. The fact that situations leading to a relative excess of estrogen or a lack of androgen are linked to a higher risk of breast cancer raises additional concerns about the use of finasteride in women. Because the inhibition of DHT formation changes the estrogen: androgen ratio and causes testosterone to be converted to estradiol by aromatase, using finasteride may result in an excess of estrogen.

The implicit consequences of women's elevated estrogen situations Finasteride use have not yet been the subject of any disquisition. Because of this, women who have a particular or family history of bone cancer are advised not to use finasteride.

2. Dutasteride

As a 5a- reductase asset, dutasteride lowers DHT serum situations by 90 as opposed to 70 for finasteride and inhibits the exertion of both type 1 and type 2 isoenzymes [84]. Worldwide, dutasteride 0.5 mg daily is authorized for the treatment of BPH; still, only a numerous nation, analogous as Korea and Mexico, have approved it for the treatment of AGA. Only a small number of randomized, placebo- controlled studies have examined dutasteride's effectiveness in treating MAGA until date.

The first RCT assessing the goods of finasteride 5 mg, dutasteride 0.05, 0.1, 0.5, or 2.5 mg, and a placebo was published in 2006 by Olsen and associates. It involved 416 males with AGA and lasted for 24 weeks. The results showed that finasteride 5 mg was less effective than dutasteride 2.5 mg at raising hair count. also, a Phase III disquisition conducted in 2010 on 153 men revealed that using 0.5 mg of dutasteride daily for 6 months increased hair growth and was well- permitted, with no significant differences in side events when compared to the placebo group.

Finasteride and dutasteride may be equally salutary in treating AGA, according to a meta analysis done in 2014 by Gupta and Charrette. That same time, still, an RCT comparing finasteride 1 mg quotidian and placebo with dutasteride 0.02, 0.1, and 0.5 mg daily in 917 men over a 24- week period showed that dutasteride 0.5 mg was statistically better than finasteride 1 mg and placebo at adding hair viscosity and count after 24 weeks [85]. Additionally, there is a case series demonstrating the effectiveness of dutasteride in males with AGA who are resistant to finasteride, and reports indicate that concurrent therapy with both medications yields better results. There were no appreciable variations in the adverse events between the treatment groups and placebo in any of the RCTs assessing dutasteride in MAGA. However, BPH patients have been treated in most of the large dutasteride trials.

Sexual adverse effects were more common with Dutasteride than with placebo in the first six months, according to safety and tolerability data from three two-year, placebo-controlled trials involving 4300 men taking the medication. These included decreased libido (3.0% dutasteride vs. 1.4% placebo), erectile dysfunction (4.7% dutasteride vs. 1.7% placebo), and ejaculation dysfunction (1.4% dutasteride vs. 0.5% placebo). But after 24 months, there was no discernible difference in the onset of new side effects compared to a placebo.

The dutasteride studies that are currently accessible in MAGA are brief. Long-term studies with placebo control include. To confirm dutasteride's treatment efficacy and safety, both finasteride and dutasteride groups are needed. Data on women are extremely limited. The effectiveness of dutasteride 0.5 mg daily for six months in treating a 46- time-old lady with FAGA who had a poor response to finasteride and topical minoxidil has only been proved in one case report. There were no negative consequences. 2.1.3 Finasteride Topical 45 MAGA cases shared in a short RCT in 2009 to assess the remedial goods of oral and topical finasteride. Over the course of six months, one group was given 1 finasteride topical gel and placebo tablets, while another group was given 1mg finasteride tablets and a placebo gel base. The size of the bald patch, hair count, and hair consistence didn't significantly change between the two groups, indicating that the finasteride tablet and gel had similar remedial goods.

Neither of the two treatment groups endured any negative sexual consequences [86]. In a 2014 exploration of 24 men with AGA, the goods of a finasteride 0.25 percent topical result and a finasteride 1 mg tablet on tube androgen situations were examined. After seven days of treatment, this trial revealed a analogous and considerable repression of tube DHT in both groups, which raises questions regarding the topical result's systemic immersion. The same authors lately examined the goods of finasteride 0.25 percent at varying tablets on the crown and serum DHT in a new topical carrier. They demonstrated that there was a considerable drop in the crown DHT position but only a 24 – 26 drops in the serum DHT when this result was given formerly daily at boluses of 100 and 200 lL.

According to these pens, topical operation's dropped immersion may, in proposition, lower the liability of any negative goods. The information is still primary, however, and implicit impurity of pregnant women should be considered when agitating topical remedies. 2.1.4 New Topical Antiandrogen Solution A phase II trial is presently being conducted on a new topical antiandrogen for the treatment of AGA called Cortexolone 17apropionate (CB-03-01) result 5 (Intrepid rectifiers, Inc., San Diego, CA, USA). The trial will examine 90 manly AGA cases' safety and effectiveness after using this admixture doubly daily for over to 26 weeks. Although no primary data are yet available, the company website states that this drug works by reducing situations of prostaglandin D2(PGD2) and blocking DHT relations with hair follicle androgen receptors [87].

5. THE ROLE OF GENETICS

About 80 of the propensity to baldness is caused by AGA vulnerability, which is substantially told by inheritable factors. The wide range of clinical symptoms and early differences seen in people with AGA are explained by the polygenic model of the illness, which is defined by different expression situations.

AGA, is caused by changes to the androgen receptor (AR) genes on the Xq12 chromosome, which raise AR gene exertion in hair follicles in response to DHT list. Unknown is the medium underpinning AR-intermediated hair loss. Nevertheless, FPHL is linked to gene variants in the AR gene, which constantly connect with men's AGA vulnerability About 40 of the heredity of AGA in men can be attributed to variation in the AR gene, and the DNA variation that causes hair loss is located near the AR locus in areas where AR has a nonsupervisory influence, similar as the Ectodysplasin A2 Receptor (EDA2R). Research has exfoliated

some light on the complex heredity of AGA, showing that genetics and androgens interact reciprocally, as demonstrated by the development of alopecia in people from families with bald adult males after entering androgenic remedy.

The role of steroid 5-alpha reductase (SRD5A) enzyme

There are five members of the SRD5A enzyme, which is a complete membrane- bedded protein SRD5A type 1 through type 3, glycoprotein synaptic 2 (GSPN2), and GSPN2- suchlike.

SRD5A1 metabolizes neurosteroids and is primarily set up in the liver, skin, and crown. Hair follicles, the prostate, and the genitourinary tract all express SRD5A2, which has a high selectivity for steroids with the- keto structure, similar as testosterone. SRD5A2 is the one linked to AGA and was linked by its capacity to transfigure- keto steroids into metabolites with certain predefined functions26. Prostate cancer, bone cancer, and nasty mortal prostate napkins all produce SRD5A3, which is involved in protein N- linked glycosylation.

Three metabolic pathways — corrosiveness acid biosynthesis, androgen metabolism, and estrogen metabolism — are intermediated by SRD5A. SRD5A uses NADPH to break down Δ 4,5 bonds in substrates in androgen metabolism. For case, SRD5A1 turns testosterone into DHT, which causes BPH, and SRD5A2 is involved in AGA. The Δ4 group (double bond) of C- 19 and C- 21 steroids is broken down by these two iso- enzymes producing the 5α- stereoisomers, DHT.



Figure 1: SRD5A2 synthesizes dihydrotestosterone (DHT) in AGA. In the presence of NADPH, testosterone is converted to DHT by the SRD5A2 enzyme.

6. DIAGNOSIS

Hair and crown examinations that reveal on- scarring alopecia in the typical pattern distribution are generally used to clinically diagnose androgenetic alopecia. In order to rule out other possible judgments, analogous as circumlocutory telogen scrap, alopecia areata, and cicatricial alopecia, the clinical examination should also involve a pull test and a review of the hair on the face, body, and nails [88]. Because androgenetic alopecia is so common, it's important to consider how it may coincide with other hair conditions.

Fresh individual procedures, similar as hair root examinations, laboratory testing, or histology, may be salutary if a discrimination opinion can not be clinically ruled out. Hair loss patterns in men and women are analogous, but they also differ greatly in how they manifest and are treated. Gender differences live in hair loss patterns and treatment response. Advanced ADA is diagnosed clinically. Still, both invasive and noninvasive ways, including crown dermoscopy, hair/ crown examination, pull tests, trichograms, and crown necropsies, are used to estimate cases for early AGA.

Follicle miniaturization, perifollicular inflammation, fibrosis in the pilosebaceous unit angiofibrotic pathways, follicular stelae, and suggestions of follicle death or hair shaft damage are histological characteristics of AGA. In order to rule out other crown diseases like seborrheic dermatitis, which can complicate AGA and produce smooth, lustrous skin, evaluation is essential. FDA- approved and non approved specifics that are said to effectively decelerate down the progression of hair loss are used to manage AGA. It's pivotal to flash back that stopping treatment could beget hair loss to worsen snappily.

7. EVALUATION

Clinical assessment is typically used to identify androgenetic alopecia, which is characterized by a history of progressive onset following puberty and frequently, though not always, a family history of baldness. Unless the diagnosis is still ambiguous, a biopsy is typically not required. Miniaturized hair and brown peripilar casts can be seen by dermoscopy, which helps differentiate it from diffuse alopecia areata, which is similar to male pattern baldness. Exclamation point hairs and other tapered fractures are indicative of diffuse alopecia areata [89]. To rule out other causes of hair loss and to find probable triggers for the emergence of androgenetic alopecia, a thorough assessment of systems, medical history, and current drug regimen is necessary. Thyroid tests, a complete blood count, and screening for iron deficiency using measurements of serum ferritin, total iron binding capacity, and iron levels are possible additional investigations. Syphilis screening may also be considered if suspicions are raised. Additionally, all patients seeking dermatological evaluation for hair loss may also benefit from a quick psychological assessment to detect indications of depressed symptoms and other psychiatric illnesses.

8. ENHANCING HEALTHCARE TEAM OUTCOMES

A common disorder that can have a major effect on both men's and women's appearance and self-esteem is androgenetic alopecia. Dermatology clinics frequently deal with alopecia, but many patients are too ashamed to seek medical help and instead turn to internet resources. Patient education is crucial to treating this disease. An interprofessional team of medical professionals frequently collaborates to provide comprehensive care for patients with androgenetic alopecia. The following are some methods that an interprofessional team can work together to treat androgenetic alopecia:

Dermatologist: - The main medical professional in charge of relating and treating androgenetic alopecia. They're suitable to do a comprehensive assessment, suggest suitable curatives, and track the development of the disease.

Primary care physician: - During routine check- ups, PCPs including croakers and advanced interpreters can play a pivotal part in determining threat factors for androgenetic alopecia. In addition to coordinating general healthcare, they could shoot cases to dermatologists for specialist treatment.

Pharmacist: - druggist Cases can profit from the druggist's knowledge of medicines like minoxidil and finasteride that are used to treat androgenetic alopecia. In order to make sure cases follow their treatment programs, they might offer information on applicable operation, possible adverse goods, and medicine.

Endocrinologist: - To estimate and treat hormonal problems causing androgenetic alopecia, an endocrinologist may be consulted in situations where hormonal abnormalities are suspected.

Plastic surgeon: - When medical treatments for advanced androgenetic alopecia have n't shown acceptable results, cases may seek hair transplant surgery. These operations can be carried out by plastic surgeons.

Nutritionist/ Dietitian: - Hair health can be told by salutary variables. Dietitians and nutritionists can advise on salutary variations and salutary supplements that could support healthy hair development.

Psychologist: - People who lose their hair may witness serious cerebral goods. By furnishing ways to enhance body image and tone- regard, psychologists and counselors can help cases in managing the cerebral and emotional impacts of hair loss.

The results of curatives for androgenetic alopecia are still uncertain, indeed with the vacuity of multitudinous medicines and hair transplant operations. For people who are n't greatly concerned by hair thinning, a simple consolation that this is a benign illness may be enough. It's imperative that druggists and clinicians work together to educate cases about this emotionally trying content, making sure they're apprehensive of the troubles, options, and anticipated results [90].

CONCLUSION

A full-picture way works best for dealing with hair loss since it’s not just one thing causing it. Because this condition ties together body, mind, and life around us, seeing those links helps tailor care while building real empathy. Hair falling out affects more than skin - it hits how people see themselves - so moving forward, focus should shift toward kindness, personal strength, and truly listening to patients figuring out what works

REFERENCE

1. Hamilton JB. Patterned loss of hair in man: types and incidence. Ann N Y Acad Sci.
    a. 1951; 53:708–28.
2. Birch MP, Messenger AG. Genetic factors predispose to balding and non-balding in men. Eur J Dermatol. 2001; 11:309–14.
3. Gan DC, Sinclair RD. Prevalence of male and female pattern Hair loss in Maryborough. J Investig Dermatol Symp Proc. 2005; 10:184–9.
4. Lee WS, Lee HJ. Characteristics of androgenetic alopecia in Asian. Ann Dermatol.

5. 2012;24(3):243–52.

6. Bas Y, Seckin HY, Kalkan G, Takci Z, Citil R, O¨ nder Y, et al.

7. Prevalence and types of androgenetic alopecia in north Anatolian population: a communitybased study. J Pak Med Assoc.2015;65(8):806–9.

8. Ku¨ster W, Happle R. The inheritance of common baldness: two B or not two B? J Am Acad Dermatol. 1984;11(5 Pt 1):921–6.

9. Yip L, Rufaut N, Sinclair RD. Role of genetics and sex steroid Hormones in male androgenetic alopecia and female pattern hair J.B. Hamilton, Patterned loss of hair in man; types and incidence. Ann. N. Y. Acad. Sci. 53, 708–728 (1951)

10. L. Yip, S. Zaloumis, D. Irwin, G. Severi, J. Hopper, G. Giles, S. Harrap, R. Sinclair, J. Ellis, Gene-wide association study Between the aromatase gene (CYP19A1) and female pattern hair Loss. Br. J. Dermatol. 161, 289–294 (2009)

11. G. Severi, R. Sinclair, J.L. Hopper, D.R. English, M.R.E. McCredie, P. Boyle, G.G. Giles, Androgenetic alopecia in men Aged 40–69 years: prevalence and risk factors. Br. J. Dermatol. 149, 1207–1213 (2003)

12. N. Otberg, A.M. Finner, J. Shapiro, Androgenetic alopecia. Endocrinol. Metab. Clin. N.

13. Am. 36, 379–398 (2007)

14. R. Paus, G. Cotsarelis, The biology of hair follicles. N. Engl. J. Med. 341, 491–497 (1999)

15. C. Pierard-Franchimont, G.E. Pierard, Teloptosis, a turning point In hair shedding biorhythms. Dermatology 203, 115–117 (2001)

16. W.C. Chumlea, T. Rhodes, C.J. Girman, A. Johnson-Levonas, F. R.W. Lilly, R. Wu, S.S. Guo, Family history and risk of hair loss. Dermatology 209, 33–39 (2004)

17. D. Osborn, Inheritance of baldness. Various patterns due to Heredity and sometimes present at birth—a sex-limited characterdominant in man–women not bald unless they inherit tendency from both parents. J. Hered. 7, 347–355 (1916)

18. W. Kuster, R. Happle, The inheritance of common baldness: two B or not two B? J. Am. Acad. Dermatol. 11, 921–926 (1984)

19. E. Levy-Nissenbaum, M. Bar-Natan, M. Frydman, E. Pras, Confirmation of the association between male pattern baldness and the androgen receptor gene. Eur. J. Dermatol. 15, 339–340 (2005)

20. Shaw JC. Antiandrogen therapy in dermatology. Int J Dermatol. 1996;35(11):770–8.

21. Burke BM, Cunliffe WJ. Oral spironolactone therapy for female

22. Patients with acne, hirsutism or androgenic alopecia. Br J Dermatol. 1985; 112:124–5.

23. Camacho-Martı´nez FM. Hair loss in women. Semin Cutan Med Surg. 2009; 28:19–32.

24. Rathnayake D, Sinclair R. Innovative use of spironolactone as an antiandrogen in the treatment of female pattern hair loss. Dermatol Clin. 2010;28(3):611–8.

25. Sinclair R, Wewerinke M, Jolley D. Treatment of female pattern Hair loss with oral antiandrogens. Br J Dermatol. 2005;152: 466–73.
26. Plovanich M, Weng QY, Mostaghimi A. Low usefulness of Potassium monitoring among healthy young women taking spironolactone for acne. JAMA Dermatol. 2015;151(9):941–4.
27. Peereboom-Wynia JD, van der Willigen AH, van Joost T, Stolz E. The effect of cyproterone acetate on hair roots and hair shaft Diameter in androgenetic alopecia in females. Acta Derm Venereol. 1989; 69:395–8.
28. Vexiau P, Chaspoux C, Boudou P, et al. Effects of minoxidil 2 % vs. Cyproterone acetate treatment on female androgenetic Alopecia: a controlled, 12-month randomized trial. Br J Dermatol. 2002; 146:992–9.
29. Blumeyer A, Tosti A, Messenger A, et al. Evidence-based (S3) Guideline for the treatment of androgenetic alopecia in women and in men. J Dtsch Dermatol Ges. 2011;9(Suppl 6): S1–57.
30. van Zuuren EJ, Fedorowicz Z, Carter B, Andriolo RB, Schoones J. Interventions for female pattern hair loss. Cochrane Database Syst Rev. 2012;5:CD007628
31. Mella JM, Perret MC, Manzotti M, Catalano HN, Guyatt G. Efficacy and safety of finasteride therapy for androgenetic Alopecia: a systematic review. Arch Dermatol. 2010;146: 1141–50.
32. Gupta AK, Charrette A. The efficacy and safety of 5a-reductase Inhibitors in androgenetic alopecia: a network meta-analysis andbBenefit-risk assessment of finasteride and dutasteride. J Dermatol Treat. 2014;25(2):156–61.
33. Olsen EA, Whiting DA, Savin R, Rodgers Johnson-Levonas AO, Round E, et al. Global photographic assessment of men Aged 18–60 years with male pattern hair loss receiving finasteride 1 mg or placebo. J Am Acad Dermatol. 2012;67(3): 379–86.
34. Steiner JF. Clinical pharmacokinetics and pharmacodynamics of Finasteride. Clin Pharmacokinet. 1996;30(1):16–27.
35. Becker CD, Stichtenoth DO, Wichmann MG, Schaefer C, Szinicz L. Blood donors on medication—an approach to minimize Drug burden for recipients of blood products and to limit deferral of donors. Transfus Med Hemother. 2009;36(2):107–13.
36. Propecia [package insert]. White House Station: Merck and Co., Inc.; 2004.
37. Whiting DA, Olsen EA, Savin R, Halper L, Rodgers A, Wang L, Et al. Efficacy and tolerability of finasteride 1 mg in men aged 41 to 60 years with male pattern hair loss. Eur J Dermatol. 2003; 13:150–60.
38. Irwig MS, Kolukula S. Persistent sexual side effects of finasteride for male pattern hair loss. J Sex Med. 2011; 8:1747–53.
39. Irwig MS. Persistent sexual side effects of finasteride: could They be permanent? J Sex Med. 2012; 9:2927–32.
40. Irwig MS. Depressive symptoms and suicidal thoughts among Former users of finasteride with persistent sexual side effects. J Clin Psychiatry. 2012; 73:1220–3.

41. Belknap SM, Aslam I, Kiguradze T, Temps WH, Yarnold PR, Cashy J, et al. Adverse event reporting in clinical trials of Finasteride for androgenic alopecia: a meta-analysis. JAMA Dermatol. 2015;151(6):600–6.
42. Traish AM, Hassani J, Guay AT, Zitzmann M, Hansen ML. Adverse side effects of 5alphareductase inhibitors therapy: Persistent diminished libido and erectile dysfunction and Depression in a subset of patients. J Sex Med. 2011; 8:872–84.
43. Ali AK, Heran BS, Etminan M. Persistent sexual dysfunction and suicidal ideation in young men treated with low-dose Finasteride: a pharmacovigilance study. Pharmacotherapy. 2015;35(7):687–95.
44. Singh MK, Avram M. Persistent sexual dysfunction and Depression in finasteride users for male pattern hair loss: a Serious concern or red herring? J Clin Aesthet Dermatol. 2014;7(12):51–5.
45. Cash TF. The psychosocial consequences of androgenetic Alopecia: a review of the research literature. Br J Dermatol. 1999;141(3):398–405.
46. Cash TF. The psychology of hair loss and its implication for patient care. Clin Dermatol. 2001;19(2):161–6.
47. Cash TF. Attitudes, behaviors, and expectations of men seeking medical treatment for male pattern hair loss: results of Multinational survey. Curr Med Res Opin. 2009;25(7):1811–20.
48. Yamazaki M, Miyakura T, Uchiyama M, Hobo A, Irisawa R, Tsuboi R. Oral finasteride improved quality of life of androgenetic alopecia patients. J Dermatol. 2011;38(8):7737.
49. Mansouri P, Farshi S, Safar F. Finasteride-induced gynecomastia. Indian J Dermatol Venereol Leprol. 2009;75(3):309–10.
50. Ramot Y, Czarnowicki T, Zlotogorski A. Finasteride induced Gynecomastia: case report and review of the literature. Int J Trichology. 2009;1(1):27–9.
51. Ferrando J, Grimalt R, Alsina M, Bulla F, Manasievska E. Unilateral gynecomastia induced by treatment with 1 mg of oral Finasteride. Arch Dermatol. 2002;138(4):5434.
52. Glina S, Neves PA, Saade R, Netto NR Jr, Soares JB, Galuppo AG. Finasteride-associated male infertility. Rev Hosp Clin Fac Med Sao Paulo. 2004;59(4):203–5.
53. Liu KE, Binsaleh S, Lo KC, Jarvi K. Propecia-induced spermatogenic failure: a report of two cases. Fertil Steril. 2008 Sep;90(3): 849.e17-9.
54. Chiba K, Yamaguchi K, Li F, Ando M, Fujisawa M. Finasterideassociated male infertility. Fertil Steril. 2011;95(5): 1786.e9–11.
55. Overstreet JW, Fuh VL, Gould J, Howard SS, Lieber MM, Hellstrom W, et al. Chronic treatment with finasteride daily Does not affect spermatogenesis or semen production in young Men. J Urol. 1999;162(4):1295–300.
56. Amory JK, Wang C, Swerdloff RS, et al. The effect of 5alphareductase inhibition with dutasteride and finasteride on semen Parameters and serum hormones in healthy men. J Clin Endocrinol Metab. 2007;92(5):1659–65.
57. Samplaski MK, Lo K, Grober E, Jarvi K. Finasteride use in the Male infertility population:
58. effects on semen and hormone Parameters. Fertil Steril. 2013;100(6):1542–6.

59. Pole M, Koren G. Finasteride. Does it affect spermatogenesis and pregnancy? Can Fam Physician. 2001; 47:2469–70.
60. D'Amico AV, Roehrborn CG. Effect of 1 mg/day finasteride on Concentrations of serum prostate-specific antigen in men with Androgenic alopecia: a randomised controlled trial. Lancet Oncol. 2007; 8:21–5.
61. Guess HA, Gormley GJ, Stoner E, Oeserling JE. The effect of Finasteride on prostate specific antigen: review of available data. J Urol. 1992; 155:3–9.
62. Oesterling JE, Roy J, Agha A, Shown T, Krarup T, Johansen T, Et al. Biologic variability of prostate-specific antigen and its Usefulness as a marker for prostate cancer: effects of finasteride. Urology. 1997; 50:13–8.
63. Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med. 2003;349(3):215–24.
64. Andriole GL, Bostwick DG, Brawley OW, Gomella LG, Marberger M, Montorsi F, REDUCE Study Group, et al. Effect of Dutasteride on the risk of prostate cancer. N Engl J Med. 2010;362(13):1192–202.
65. Lynn R, Krunic A. Therapeutic hotline. Treatment of androgenic Alopecia with finasteride may result in a high-grade prostate Cancer in patients: fact or fiction? Dermatol Ther. 2010; 23:544–6.
66. Tru¨eb RM, Swiss Trichology Study Group. Finasteride treatment of patterned hair loss in normoandrogenic postmenopausal Women. Dermatology. 2004; 209:202–7.
67. Kohler C, Tschumi K, Bodmer C, Schneiter M, Birkhaeuser M. Effect of finasteride 5 mg (Proscar) on acne and alopecia in Female patients with normal serum levels of free testosterone. Gynecol Endocrinol. 2007;23(3):142–5.
68. Stout SM, Stumpf JL. Finasteride treatment of hair loss in Women. Ann Pharmacother. 2010;44(6):1090–7.
69. Boersma IH, Oranje AP, Grimalt R, Iorizzo M, Piraccini BM, Verdonschot EH. The effectiveness of finasteride and dutasteride used for 3 years in women with androgenetic alopecia. Indian J Dermatol Venereol Leprol. 2014; 80:521–5.
70. Iorizzo M, Vincenzi C, Voudouris S, Piraccini BM, Tosti A. Finasteride treatment of female pattern hair loss. Arch Dermatol. 2006; 142:298–302.
71. Price VH, Roberts JL, Hordinsky M, Olsen EA, Savin R, Bergfeld W, et al. Lack of efficacy of finasteride in postmenopausal women with androgenetic alopecia. J Am AcadnDermatol. 2000; 43:768–76.
72. Whiting DA, Waldstreicher J, Sanchez M, Kaufman KD. Measuring reversal of hair miniaturization in androgenetic alopecia By follicular counts in horizontal sections of serial scalp biopsies: Results of finasteride 1 mg treatment of men and postmenopausal Women. J Investig Dermatol Symp Proc. 1999; 4:282–4.
73. Van Zuuren EJ, Fedorowicz Z, Carter B. Evidence-based treatments for female pattern hair loss: a summary of a Cochrane Systematic review. Br J Dermatol. 2012; 167:995–1010.

74. Yeon JH, Jung JY, Kim BJ, Youn SW, Park KC, et al. 5 mg/day finasteride treatment for normoandrogenic Asian Women with female pattern hair loss. J Eur Acad Dermatol Venereol. 2011;25(2):211–4.
75. Bowman CJ, Barlow NJ, Turner KJ, Wallace DG, Foster PM. Effects of in utero exposure to finasteride on androgen-dependent reproductive development in the male rat. Toxicol Sci. 2003; 74:393–406.
76. Roussouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stafanick ML, et al. Risks and benefits of Estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002; 288:321–33.
77. Clark RV, Hermann DJ, Cunningham GR, Wilson TH, Morrill BB, Hobbs S. Marked suppression of dihydrotestosterone in Men with benign prostatic hyperplasia by dutasteride, a dual 5-alpha-reductase inhibitor. J Clin Endocrinol Metab. 2004; 89:2179–84.
78. Olsen EA, Hordinsky M, Whiting D, Stough D, Hobbs S, Ellis ML, et al. Dutasteride Alopecia Research Team. The importance of dual 5alpha-reductase inhibition in the treatment of male Pattern hair loss: results of a randomized placebo-controlled Study of dutasteride versus finasteride. J Am Acad Dermatol. 2006; 55:1014–23.
79. Eun HC, Kwon OS, Yeon JH, Shin HS, Kim BY, Ro BI, et al. Efficacy, safety, and tolerability of dutasteride 0.5 mg once Daily in male patients with male pattern hair loss: a randomized, Double-blind, placebo-controlled, phase III study. J Am Acad Dermatol. 2010; 63:252–8.
80. Harcha WG, Barboza Martı´nez J, Tsai TF, Katsuoka K, Kawashima M, Tsuboi R, et al. A randomized, active-and placebo-controlled study of the efficacy and safety of different Doses of dutasteride versus placebo and finasteride in the treatment of male subjects with androgenetic alopecia. J Am Acad Dermatol. 2014;70(3):489–98.
81. Boyapati A, Sinclair R. Combination therapy with finasteride and low-dose dutasteride in the treatment of androgenetic Alopecia. Australas J Dermatol. 2013;54(1):49–51.
82. Jung JY, Yeon JH, Choi JW, Kwon SH, Kim BJ, Youn SW, Et al. Effect of dutasteride 0.5 mg/d in men with androgenetic Alopecia recalcitrant to finasteride. Int J Dermatol. 2014;53(11):1351–7.
83. Roehrborn CG, Boyle P, Nickel JC, Hoefner K. Andriole G; ARIA3001, ARIA3002, and ARIA3003 Study Investigators. Efficacy and safety of dual inhibitor of 5-a-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology. 2002; 60:434–41.
84. Andriole GL, Kirby R. Safety and tolerability of the dual 5alpha-reductase inhibitor dutasteride in the treatment of benign Prostatic hyperplasia. Eur Urol. 2003;44(1):828.
85. Olszewska M, Rudnicka L. Effective treatment of female. Androgenic alopecia with dutasteride. J Drugs Dermatol. 2005;4: 637–40.
86. Hajheydari Z, Akbari J, Saeedi M, Shokoohi L. Comparing the Therapeutic effects of finasteride gel and tablet in treatment of the androgenetic alopecia. Indian J Dermatol Venereol Leprol. 2009; 75:47–51.

87. Caserini M, Radicioni M, Leuratti C, Annoni O, Palmieri R. A Novel finasteride 0.25 % topical solution for androgenetic Alopecia: pharmacokinetics and effects on plasma androgen Levels in healthy male volunteers. Int J Clin Pharmacol Ther. 2014;52(10):842–1.
88. Caserini M, Radicioni M, Leuratti C, Terraqni E, Iorizzo M, Palmieri R. Effects of a novel finasteride 0.25 % topical solution On scalp and serum dihydrotestosterone in healthy men with Androgenetic alopecia. Int J Clin Pharmacol Ther. 2016;54(1):19–27.
89. Andrasfay A; Intrepid Therapeutics, Inc. A phase 2 study to Evaluate the safety and efficacy of CB-03-01 solution, a comparator solution and vehicle solution in males with androgenetic Alopecia [ClinicalTrials.gov identifier NCT02279823]. US
90. National Institutes of Health, ClincalTrials.gov. https://clinical Trials.gov/ct2/show/NCT02279823. Accessed 16 September 2025.
91. Cassiopea. BreezulaTM.
    a. http://www.cassiopea.com/activities/Productpipeline/breezula.aspx. Accessed 16 September 20125.
92. Reveals new candidate genes for androgenetic alopecia J Invest Dermatol, 136 (2016), pp. 1559-1567 View PDF View articleView in Scopus Google Scholar.
93. Q. Xiao, L. Wang, S. Supekar, et al. Structure of human steroid 5α-reductase 2 with the anti-androgen drug finasteride Nat Commun, 11 (2020), pp. 1-11 Google Scholar.